Intro to COVID-19: Defining Emergency Use Authorization (EUA) Authorities
This session will address general regulatory requirements for bringing a medical product to market under emergency use authorities in the Federal Food, Drug, and Cosmetic Act.
Cathy L. Burgess, Partner, Alston & Bird LLP, Member, FDLI Board of Directors
This session was recorded as part of FDLI’s virtual course, “COVID-19: Introduction to FDA’s Existing Legal Authorities and Emerging Issues” in August 2020.
- +$100 for nonmembers
Legal issues regarding the response to COVID-19 is a rapidly evolving field. It is important to note the program recording date given that FDA guidance may have revised or been updated. For questions, please check the FDA website at: https://www.fda.gov/home
Virtual Learning FAQ